Breaking into the Biologics and Biosimilars Market: Devising Forward-Thinking Portfolio Strategies
Alicia A. Russo
Partner
Venable LLP
Hans Sauer, Ph.D., J.D.
Deputy General Counsel, VP of IP
Biotechnology Innovation Organization
Eamonn Gardner
Partner
Cooley LLP
- Reviewing the biggest deals and acquisitions in the market place
- Evaluating the clinical pipeline by company, indication and phase
- Analyzing the market share for biosimilars in the U.S. and abroad
- Target drugs with highest spending
- Current market dynamics and considerations for biosimilar adoption
- Utilizing historical biosimilar trends to provide potential future biosimilar spending and saving scenarios
- Considering partnership agreements to offset capital costs and risk of biosimilar development and production